Chronic spontaneous urticaria (CSU) is a mast cell–driven skin disease characterized by the
recurrence of transient wheals, angioedema, or both for more than 6 weeks. Autoimmunity is …

This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the
primary effector cell in urticaria. Mast cells are located in the upper dermis, the ideal situation …

Background Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of
chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies to IgE or its high …

Background Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic
spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias …

This update on chronic urticaria (CU) focuses on the prevalence and pathogenesis of
chronic spontaneous urticaria (CSU), the expanding spectrum of patient-reported outcome …

The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug
approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who …

The discovery of IgE represented a major breakthrough in allergy and asthma research,
whereas the clinical interest given to IgE in asthma has been blurred until the arrival of anti …

Background Omalizumab is an effective and well‐tolerated treatment for chronic
spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but …

Urticaria is a common clinical condition presenting with wheals (hives), angioedema, or
both. Urticaria has a complex pathogenesis, along with a high disease burden, a significant …

5. Andersen YM, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of
myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic …